Since TRAIL preferentially kills tumour cells while sparing normal healthy cells, TRAIL and agonistic anti-TRAIL-R1 and TRAIL-R2 antibodies were developed for treatment of different malignancies [11,12,13]. Here, TNFRSF10A is linked to neoplasm.